MapLight Therapeutics (MPLT) Capital Expenditures (2024 - 2025)

MapLight Therapeutics (MPLT) posted Capital Expenditures of $376000.0 for Q4 2025, up 254.72% sequentially from $106000.0 in Q4 2024, and up 254.72% YoY from $106000.0 in Q4 2024.

MapLight Therapeutics (MPLT) Capital Expenditures (2024 - 2025) Analysis & Trends

MapLight Therapeutics has reported Capital Expenditures for 2 years, with the latest figure at $376000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 112.20 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 240.20 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 2.29 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 25.02 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 572,662.23
7 Royalty Pharma 33.72 Bn 35.84 Bn - 251.02 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 34.68 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 6.26 Mn
10 MapLight Therapeutics 533.88 Mn 533.88 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 376,000.00
Dec 31, 2025 376,000.00
Dec 31, 2024 106,000.00
Dec 31, 2024 106,000.00